Loading people...
Dan Suesskind is an Israel-based investor and board member currently serving as a corporate director for emerging healthcare and biotechnology companies, including RedHill Biopharma. He is widely recognized for his 31-year tenure as the Chief Financial Officer of Teva Pharmaceutical Industries, where he directed the firm's global financial strategy from 1977 until his retirement in 2008. Suesskind earned a Bachelor of Arts in Economics and International Relations from the Hebrew University of Jerusalem and a Master of Business Administration from the University of Massachusetts Amherst. Throughout his extensive career, he has held prominent directorships at major regional financial institutions, including a notable board position at the Israel Corporation. His current professional focus centers on leveraging his corporate finance expertise to support early-stage technology and pharmaceutical startups in building scalable and sustainable commercial ventures.
Dan Suesskind holds the critical position of Chief Financial Officer (CFO) at Teva Pharmaceutical Industries Ltd., one of the world's largest generic drug manufacturers and a significant player in specialty pharmaceuticals. In this capacity, Mr. Suesskind is instrumental in shaping the financial direction and stability of a complex, global enterprise. His responsibilities encompass a broad spectrum of financial management, including overseeing financial planning and analysis, corporate accounting, treasury operations, tax strategy, and investor relations.
As CFO, Dan Suesskind's influence extends to Teva's strategic investment decisions. While not a traditional venture capitalist or angel investor, his role involves significant capital allocation choices that directly impact Teva's future growth and market position. This includes evaluating and funding research and development projects for new drug pipelines, assessing potential mergers and acquisitions to expand market share or therapeutic areas, and managing capital expenditures for manufacturing and operational improvements. His expertise ensures that Teva's financial resources are deployed effectively to maximize shareholder value and sustain long-term profitability in a highly competitive pharmaceutical landscape.
Mr. Suesskind's career background likely reflects extensive experience in corporate finance, possibly within the pharmaceutical industry or other large, multinational corporations. A CFO of his stature typically possesses a deep understanding of global financial markets, regulatory environments, and complex financial instruments. His leadership is crucial in navigating economic fluctuations, managing debt, and optimizing Teva's capital structure to support its strategic objectives, such as expanding into new markets or launching innovative specialty medicines. His strategic financial oversight helps Teva maintain its position as a leader in healthcare.
Key areas of focus for Dan Suesskind in his role include enhancing operational efficiency, driving cost-saving initiatives, and ensuring robust financial reporting and compliance. He plays a vital role in communicating Teva's financial performance and strategic vision to investors and analysts, fostering transparency and confidence in the company's direction. His contributions are central to Teva Pharmaceutical Industries Ltd.'s ability to innovate, grow, and continue providing essential medicines to patients worldwide, making him a pivotal figure in the company's ongoing success and financial health.
Dan Suesskind is the Chief Financial Officer (CFO) of Teva Pharmaceutical Industries Ltd., a global pharmaceutical company. In this role, he is responsible for the company's overall financial strategy, operations, and performance.
As CFO of Teva Pharmaceutical Industries Ltd., Dan Suesskind's role involves strategic financial decisions that impact Teva's corporate investments. This includes capital allocation for research and development, market expansion, potential mergers and acquisitions, and other initiatives designed to drive Teva's growth and enhance shareholder value. He focuses on optimizing the company's financial resources for strategic corporate objectives.
Dan Suesskind works at Teva Pharmaceutical Industries Ltd., where he holds the position of Chief Financial Officer. Teva is a leading global pharmaceutical company headquartered in Israel, with operations worldwide.
